Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Study finds no lung damage from common arthritis drug

NCT ID NCT07360340

First seen Jan 25, 2026 · Last updated Jun 22, 2026 · Updated 23 times

Summary

This study looked at 50 Egyptian patients with rheumatoid arthritis to see if methotrexate, a common treatment, causes lung problems. Half the patients took methotrexate, and the other half took other arthritis drugs. Researchers used lung function tests and CT scans to check for damage. They found no difference in lung health between the two groups, suggesting methotrexate may not be a major cause of lung disease in these patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METHOHEXITONE PULMONARY ADVERSE REACTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Faculty of medicine, Ain Shams University

    Cairo, Egypt

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Methotrexate

What this could lead to

If confirmed, this could reassure patients that methotrexate may not cause lung damage in rheumatoid arthritis.

What could go wrong

This was a small, single-center study with only 50 patients. Results may not apply to all populations or detect rare side effects.

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.